Lixte Biotechnology (LIXT) Competitors

→ Biden replacement revealed? (From Paradigm Press) (Ad)

$3.46

+0.11 (+3.28%)

(As of 04/19/2024 ET)

LIXT vs. OBSV, CLVR, PULM, ASLN, KTTA, TFFP, CANF, EFTR, CMMB, and CYCN

Should you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include ObsEva (OBSV), Clever Leaves (CLVR), Pulmatrix (PULM), ASLAN Pharmaceuticals (ASLN), Pasithea Therapeutics (KTTA), TFF Pharmaceuticals (TFFP), Can-Fite BioPharma (CANF), eFFECTOR Therapeutics (EFTR), Chemomab Therapeutics (CMMB), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical preparations" industry.

Lixte Biotechnology vs.

Lixte Biotechnology (NASDAQ:LIXT) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

: 5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 17.5% of ObsEva shares are owned by institutional investors. 15.5% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 14.4% of ObsEva shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
: Lixte Biotechnology has higher earnings, but lower revenue than ObsEva. Lixte Biotechnology is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lixte Biotechnology N/A N/A -$5.09M -$2.70 -1.28
ObsEva $20.11M 0.01 -$58.38M -$0.92 0.00
: ObsEva received 319 more outperform votes than Lixte Biotechnology when rated by MarketBeat users.
Company Underperform Outperform
Lixte Biotechnology N/A N/A
ObsEva Outperform Votes
319
53.89%
Underperform Votes
273
46.11%
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lixte Biotechnology
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
ObsEva
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: In the previous week, Lixte Biotechnology's average media sentiment score of 0.72 beat ObsEva's score of 0.00 indicating that Lixte Biotechnology is being referred to more favorably in the media.
Company Overall Sentiment
Lixte Biotechnology Positive
ObsEva Neutral
: ObsEva's return on equity of -416.36% beat Lixte Biotechnology's return on equity.
Company Net Margins Return on Equity Return on Assets
Lixte Biotechnology N/A -1,202.60% -119.91%
ObsEva N/A -416.36% -92.01%
: Lixte Biotechnology has a beta of -0.28, suggesting that its share price is 128% less volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$5.09M	-$2.70	-1.28
ObsEva	$20.11M	0.01	-$58.38M	-$0.92	0.00

Company	Underperform	Outperform
Lixte Biotechnology	N/A	N/A
ObsEva	Outperform Votes 319 53.89%	Underperform Votes 273 46.11%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Overall Sentiment
Lixte Biotechnology	Positive
ObsEva	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-1,202.60%	-119.91%
ObsEva	N/A	-416.36%	-92.01%

Summary

ObsEva beats Lixte Biotechnology on 8 of the 11 factors compared between the two stocks.

Ad DTI

Did you know you can now trade Bitcoin in your regular brokerage account?

You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history! That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords… Heck, you don’t even need a crypto wallet!

>> Tap here to sign up and join them for the imminent workshop

Get Lixte Biotechnology News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIXT vs. The Competition

Export to Excel

Metric	Lixte Biotechnology	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.80M	$6.12B	$4.80B	$7.30B
Dividend Yield	N/A	3.11%	2.94%	4.01%
P/E Ratio	-1.28	17.53	269.16	20.05
Price / Sales	N/A	280.36	2,453.82	89.18
Price / Cash	N/A	29.89	47.24	34.82
Price / Book	15.75	5.43	4.55	4.16
Net Income	-$5.09M	$134.01M	$104.05M	$214.20M
7 Day Performance	-0.43%	-6.65%	-4.49%	-3.51%
1 Month Performance	51.31%	-9.61%	-6.67%	-5.50%
1 Year Performance	-46.63%	-5.42%	7.72%	3.53%

Lixte Biotechnology Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBSV ObsEva	0 of 5 stars	$0.00 flat	N/A	-97.7%	$7.94M	$20.11M	0.00	48	Analyst Report News Coverage
CLVR Clever Leaves	0 of 5 stars	$4.54 -1.9%	N/A	-58.8%	$7.95M	$17.42M	-0.40	400
PULM Pulmatrix	0.9496 of 5 stars	$2.12 +1.4%	$10.00 +371.7%	-35.8%	$7.74M	$7.30M	-0.55	28	Analyst Report Gap Up
ASLN ASLAN Pharmaceuticals	2.8209 of 5 stars	$0.49 -2.0%	$11.33 +2,204.9%	-86.9%	$8.04M	$12M	-0.18	34	Upcoming Earnings News Coverage
KTTA Pasithea Therapeutics	0 of 5 stars	$7.25 +1.4%	N/A	-14.3%	$7.54M	$20,000.00	0.00	15	News Coverage Positive News
TFFP TFF Pharmaceuticals	1.8775 of 5 stars	$3.31 -6.0%	$72.00 +2,075.2%	-80.5%	$8.34M	$730,000.00	-0.26	15
CANF Can-Fite BioPharma	0.4153 of 5 stars	$2.08 +0.5%	$15.00 +621.2%	N/A	$7.36M	$740,000.00	-1.16	8
EFTR eFFECTOR Therapeutics	1.2059 of 5 stars	$1.99 +3.1%	$24.00 +1,106.0%	-83.0%	$7.34M	$3.55M	-0.12	14	Gap Down
CMMB Chemomab Therapeutics	1.446 of 5 stars	$0.66 -9.6%	$7.00 +959.5%	-59.5%	$7.30M	N/A	-0.31	20	News Coverage Gap Down
CYCN Cyclerion Therapeutics	0 of 5 stars	$3.15 -5.1%	N/A	-47.0%	$8.54M	$1.62M	-0.57	1	Short Interest ↓ News Coverage Positive News

Related Companies and Tools

Related Companies:

Top 10 Stock Comparisons

This page (NASDAQ:LIXT) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Lixte Biotechnology (LIXT) Competitors

LIXT vs. OBSV, CLVR, PULM, ASLN, KTTA, TFFP, CANF, EFTR, CMMB, and CYCN

Lixte Biotechnology vs.

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIXT vs. The Competition

Lixte Biotechnology Competitors List

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info